These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23349303)

  • 21. Prognostic significance of
    Yuan Y; Li J; Xue TL; Hu HR; Lin W; Liu SG; Zhang RD; Zheng HY; Gao C
    Leuk Lymphoma; 2022 Jul; 63(7):1624-1633. PubMed ID: 35129045
    [No Abstract]   [Full Text] [Related]  

  • 22. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.
    Clappier E; Collette S; Grardel N; Girard S; Suarez L; Brunie G; Kaltenbach S; Yakouben K; Mazingue F; Robert A; Boutard P; Plantaz D; Rohrlich P; van Vlierberghe P; Preudhomme C; Otten J; Speleman F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2010 Dec; 24(12):2023-31. PubMed ID: 20861920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NOTCH1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia.
    Natarajan V; Bandapalli OR; Rajkumar T; Sagar TG; Karunakaran N
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e23-30. PubMed ID: 25493453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
    Szarzyńska-Zawadzka B; Kunz JB; Sędek Ł; Kosmalska M; Zdon K; Biecek P; Bandapalli OR; Kraszewska-Hamilton M; Jaksik R; Drobna M; Kowalczyk JR; Szczepański T; Van Vlierberghe P; Kulozik AE; Witt M; Dawidowska M
    Am J Hematol; 2019 Apr; 94(4):E93-E96. PubMed ID: 30614545
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.
    Fogelstrand L; Staffas A; Wasslavik C; Sjögren H; Söderhäll S; Frost BM; Forestier E; Degerman S; Behrendtz M; Heldrup J; Karrman K; Johansson B; Heyman M; Abrahamsson J; Palmqvist L
    Pediatr Blood Cancer; 2014 Mar; 61(3):424-30. PubMed ID: 24424791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.
    Kimura S; Seki M; Yoshida K; Shiraishi Y; Akiyama M; Koh K; Imamura T; Manabe A; Hayashi Y; Kobayashi M; Oka A; Miyano S; Ogawa S; Takita J
    Cancer Sci; 2019 Feb; 110(2):784-794. PubMed ID: 30387229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
    Paganin M; Ferrando A
    Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of IDH1-R132H mutation in T cell acute lymphoblastic leukemia mouse model via the Notch1 pathway.
    Liu Y; Fang B; Feng X; Jiang Y; Zeng Y; Jiang J
    Tissue Cell; 2022 Feb; 74():101674. PubMed ID: 34814054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting NOTCH1 in T-ALL: Starving the dragon.
    Herranz D; Ferrando AA
    Cell Cycle; 2016; 15(4):483-4. PubMed ID: 26864725
    [No Abstract]   [Full Text] [Related]  

  • 33. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
    Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
    Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-ALL: ALL a matter of Translation?
    Girardi T; De Keersmaecker K
    Haematologica; 2015 Mar; 100(3):293-5. PubMed ID: 25740104
    [No Abstract]   [Full Text] [Related]  

  • 35. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
    Petit A; Trinquand A; Chevret S; Ballerini P; Cayuela JM; Grardel N; Touzart A; Brethon B; Lapillonne H; Schmitt C; Thouvenin S; Michel G; Preudhomme C; Soulier J; Landman-Parker J; Leverger G; Macintyre E; Baruchel A; Asnafi V;
    Blood; 2018 Jan; 131(3):289-300. PubMed ID: 29051182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?
    Goldshtein A; Berger M
    Crit Rev Oncog; 2014; 19(5):399-404. PubMed ID: 25404153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
    Mansour MR; Sulis ML; Duke V; Foroni L; Jenkinson S; Koo K; Allen CG; Gale RE; Buck G; Richards S; Paietta E; Rowe JM; Tallman MS; Goldstone AH; Ferrando AA; Linch DC
    J Clin Oncol; 2009 Sep; 27(26):4352-6. PubMed ID: 19635999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia.
    Germano G; Valsecchi MG; Buldini B; Cazzaniga G; Zanon C; Silvestri D; Te Kronnie G; Basso G; Paganin M
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28025. PubMed ID: 31571345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of NOTCH1 mutations détections in T-acute lymphoblastic leukemia patients.
    Aref S; El Agdar M; Salama O; Zeid TA; Sabry M
    Cancer Biomark; 2020; 27(2):157-162. PubMed ID: 31796666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.